Lonza Group stock gains after Morgan Stanley conference highlights CDMO growth

Published on 09/16/2026 at 15:09 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Lonza Group stock traded around CHF 540 on the SIX Swiss Exchange on September 16, 2026, leaving the shares more than 10 percent below their 52-week high. The Morgan Stanley healthcare conference underlined double-digit growth and strong cash generation in key Lonza divisions.

Schwarz-Weiß-Reportage: Wissenschaftler im Schutzanzug am Mikroskop, dokumentarischer Stil — Lonza CH0013841017 Forscher im Schutzanzug am Mikroskop dokumentarisch in Schwarz Weiss fotografiert, Illustration mit AI erstellt.

Lonza Group stock (ISIN CH0013841017) was last quoted around CHF 540 on the SIX Swiss Exchange on September 16, 2026, leaving the shares clearly below their 52-week high while still well above the yearly low. According to finanzen.ch data from September 16, 2026, the stock recently traded at CHF 540.20, up 0.6 percent intraday and roughly 10.7 percent under the 52-week high of CHF 597.80 reached on August 25, 2026.

Conference message supports CDMO growth story

As Investing.com France reported on September 16, 2026, Lonza used the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026 to present itself as a company in transition toward a pure contract development and manufacturing organization, or CDMO, model. The management reiterated a medium-term target for organic revenue growth of around 10 to 13 percent per year, supported by strong demand in biologics manufacturing and advanced synthesis services.

According to the same conference coverage by Investing.com France, the Advanced Synthesis division delivered revenue growth of 28 percent in the first half of 2026, supported by highly potent small-molecule active pharmaceutical ingredients and bioconjugation services. Management noted that this 28 percent growth and an EBITDA margin of 48 percent in Advanced Synthesis in the first half of 2026 are unlikely to be repeated, but they underline the profitability of Lonza's high-value platforms.

Segment dynamics and investment phase

As Investing.com Brazil highlighted on September 16, 2026, Lonza is close to finalizing the transition to a pure CDMO model, with the sale of 60 percent of its Capsules and Health Ingredients division expected by the end of 2026. The company indicated that capital expenditures should normalize between 14 and 19 percent of revenue over time, which it described as consistent with its targeted organic growth range of 10 to 13 percent annually.

The same conference notes from Investing.com Germany state that the Integrated Biologics segment is growing about 10 percent in 2026, with growth limited mainly by the timing of new capacity additions rather than demand weakness. For investors, this combination of double-digit growth in biologics and the strong margin profile in Advanced Synthesis supports Lonza's positioning as a premium CDMO, even as the group moves through a period of heavy investment and portfolio reshaping.

Stock valuation and recent trading range

According to an English-language summary on Investing.com Canada dated September 16, 2026, Lonza's strong operational performance has supported a market capitalization of about USD 46 billion and a price-earnings ratio near 34.7 based on current-year earnings expectations. The report noted that this valuation places Lonza stock at a premium to some peers and that the shares appear slightly overvalued relative to an estimated fair value in InvestingPro analysis, even though the underlying growth and cash generation remain attractive.

Finanzen.ch price data from September 16, 2026 show Lonza stock at CHF 540.20 at 12:28 local time, gaining 0.6 percent on the day and trading on the winner side of the Swiss Market Index around 13,861 points. In this overview, the 52-week high of CHF 597.80 on August 25, 2026 compares with a 52-week low of CHF 454.60 on March 23, 2026, so the latest quote was approximately CHF 85.6 above the low and CHF 57.6 below the high, illustrating a recovery from the lower end of the range but leaving room before a new high.

Closing price snapshot for investors

Per the latest market overview from finanzen.ch on September 16, 2026, Lonza Group stock recently changed hands at CHF 540.20 on the SIX Swiss Exchange, up 0.6 percent intraday and about 10.7 percent under the 52-week high of CHF 597.80, with the Swiss Market Index itself standing near 13,861 points. At that level, the shares remain comfortably above the 52-week low of CHF 454.60 recorded on March 23, 2026, reflecting investors' continued confidence in Lonza's CDMO growth strategy despite an ongoing phase of elevated capital expenditure.